AAA multiphase: Non-invasive Aortic Aneurysm Tissue Characterization Using Wall Viscoelasticity

Sponsor
Centre hospitalier de l'Université de Montréal (CHUM) (Other)
Overall Status
Recruiting
CT.gov ID
NCT04150653
Collaborator
McGill University (Other), University of Calgary (Other), Eindhoven University of Technology (Other)
30
1
14.8
2

Study Details

Study Description

Brief Summary

Abdominal aortic aneurysm (AAA) is an abnormal dilatation of the aorta in the abdomen due to a wall weakening caused by atherosclerosis. While indications for a rupture intervention are based on AAA maximal diameter (MaxD) (5 cm), 23% of ruptured AAAs are less than 5 cm and in large AAAs, rupture rate could be lower than expected. We propose to expand and validate our vascular ultrasound elastography software to 3D. Strain maps generated from radiofrequency (RF) data acquired from 30 AAA patients with a matrix-array 3D probe will be registered to conventional CT (phase 1) and validated to a biomechanical for characterization of AAA wall, assessing vulnerability and influence of surrounding tissues (phase 2). At the end of the project, we will have analyzed 3D strain maps to improve patient selection before surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)

Detailed Description

BACKGROUND - Abdominal aortic aneurysm (AAA) rupture is the 13th cause of death in North America. The indications for a procedure to prevent rupture are based on AAA maximal diameter. However, it is a dichotomic criteria leading to under or over estimation of rupture risk. Biomechanics based criteria have been investigated using Finite Elements Analysis (FEA). The limitation of FEA is the absence of patient specific biomechanical information. Our team have previously developped a technique to map in-vivo the strain of AAAs, named non-invasive vascular elastography by ultrasound (NIVE). However, it relies on 2D ultrasound series, whereas new matrix- array probes allow a 3D mapping of the strain at a lower temporal resolution. We propose to create a 3D mapping of AAA strain with 3D ultrasound and register the strain mapping on a single phase CT.

In the project, we plan to acquire multi-modal imaging from 30 AAA patients scheduled for an elective repair will be recruited. A 3D NIVE examination and multiphase CT will be performed on each patient within less than one month of their surgery. A portion of the AAA wall will be harvested during surgery to correlate strains with tensile tests and histology. Following the implementation of NIVE processing and 3D registration, the NIVE and multiphase CT strain values will be calculated and if necessary controlled for the measurement of blood pressure, AAA maximal diameter, calcium load, gender and age. A FEA model developed at U of Calgary will be personalized using the calculation of in-vivo strains. Comparison of strain measurement between NIVE and multiphase CT, correlation of strain measurements and personalized FEA with AAA growth will constitute secondary endpoints. Following the complete validation of this personalized model, we anticipate this will provide predictive biomarkers for AAA vulnerability.

OBJECTIVES - Primary objectives: 1. Acquire a multimodal image dataset (multiphase CT, 3D US) from 30 AAA patients undergoing repair surgery (phase 1); 2. Optimize and validate in vitro the NIVE acquisition protocol and the image registration algorithm between NIVE and one phase of the multiphase CT (phase 1); 3. Compare the principal strain distribution assessed with 3D NIVE registered on conventional CT and those imaged with multiphase CT acquisition (phase 1); 4. Validate both approaches with histology and tensile test on AAA samples (phase 2).

Main hypothesis: Strain maps with 3D NIVE registered on single phase CT provide an accurate in-vivo estimation of AAA wall strength and yield similar accuracy to strain from multiphase CT to assess AAA vulnerability.

METHODOLOGY ** Phase 1 only will be done for the moment** - Design: We plan a prospective study involving 30 AAA patients scheduled for elective open repair. For the phase 1 of the study, we will perform in all patients a NIVE examination and multiphase CT within less than one month of their surgery. For the phase 2 of the study, patient undergoing open surgery will be recruited. A portion of the AAA wall will be harvested during surgery (outside of scope of the pilot study) in order to perform biaxial tensile tests and histology examination. Patients will be recruited at the Centre hospitalier de l'Université de Montréal (CHUM) and Glen campus McGill University.

Data analysis: Spearman correlation, accuracy evaluated by mean error and standard deviation, intraclass correlation coefficient, Bland-Altmann analysis, mixed linear model to evaluate the influence of sex, MaxD, pulse pressure, calcification score on strain (NIVE, multiphase CT) measurements.

RATIONALE AND IMPACT - Ruptured AAA (rAAA) is a life-threatening situation which is the 13th mortality cause in USA. Endovascular aneurysm repair (EVAR) is often preferred for rAAA for its lower morbidity and mortality as compared with OR (1.6 versus 5%). But these data show the maximal diameter/rupture relationship to be nonlinear and inaccurate to predict rupture. New imaging biomarkers to predict AAA growth and rupture are therefore needed. There is also a need to personalize the tissue modeling with in vivo assessment of AAA wall strain to improve prediction of AAA rupture or growth. At the end of the study, we anticipate to have complete validation of this non-invasive assessment of AAA wall vulnerability using US-CT fusion,that will constitute the basis of a personalized assessment of AAA vulnerability. The strain mapping can be used to improve patient selection or be incorporated in a FEA model. Our personalized predictive model will also be useful for EVAR procedure simulation, planning and guidance.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Non-invasive Aortic Aneurysm Tissue Characterization Using Wall Viscoelasticity
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Nov 25, 2021
Anticipated Study Completion Date :
Nov 25, 2021

Arms and Interventions

Arm Intervention/Treatment
AAA patients

All patients enrolled in phase 1 will undergo: Multiphase scan CT Non-invasive vascular ultrasound elastography by ultrasound (NIVE)

Device: Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
Other Names:
  • Multiphase scan CT
  • Non-invasive vascular ultrasound elastography by ultrasound (NIVE)
  • Outcome Measures

    Primary Outcome Measures

    1. AAA strain measurement [Within less than one month of their surgery]

      Measure of AAA strain values using imaging exams

    Secondary Outcome Measures

    1. AAA strain measurement determined by NIVE [Within less than one month of their surgery]

      Measure of AAA strain using non-invasive vascular elastography by ultrasound (NIVE)

    2. AAA strain measurement determined by multiphase CT [Within less than one month of their surgery]

      Measure of AAA strain using multiphase CT scan

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient with a documented AAA (CT-scan or ultrasound less than 6 months before enrollment) with a maximum diameter (max D) between 4.5 cm and 7 cm.
    Exclusion Criteria:
    • Ruptured, symptomatic or not atheromatous aneurysm;

    • Renal failure (renal serum clearance <50 mL/min);

    • Previous intervention on AAA (general or endovascular surgery);

    • BMI >35;

    • Atrial fibrillation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre Hospitalier de l'Université de Montréal Montréal Quebec Canada H2X 0C1

    Sponsors and Collaborators

    • Centre hospitalier de l'Université de Montréal (CHUM)
    • McGill University
    • University of Calgary
    • Eindhoven University of Technology

    Investigators

    • Principal Investigator: Samuel Kadoury, PhD, Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM) and Polytechnique Montréal

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Centre hospitalier de l'Université de Montréal (CHUM)
    ClinicalTrials.gov Identifier:
    NCT04150653
    Other Study ID Numbers:
    • MP-02-2020-8429
    First Posted:
    Nov 5, 2019
    Last Update Posted:
    Aug 6, 2021
    Last Verified:
    Jan 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 6, 2021